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Abstract

CHARACTERIZATION OF THE MYCOBACTERIUM TUBERCULOSIS TRMD
By Zohal Hamidi
Bachelor of Science, Virginia Polytechnic Institute & State University, 2006
A thesis submitted in partial fulfillment of the requirements for the degree of Master’s of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2010

Major Director: Dr. Walter M. Holmes
Biochemistry Professor in Department of Microbiology & Immunology

One third of the world’s population is affected by Tuberculosis (TB), a disease
caused by infection with Mycobacterium tuberculosis. The emergence of multidrugresistant MtB makes this disease a major public health concern. New agents are needed to
treat TB infections in a manner that circumvents existing pathways of resistance. One
strategy is to target the organism at the translational level by inhibiting vital modifications
of RNA. One gene responsible for these modifications is the tRNA (guanosine-1)methyltransferase, trmD, which has been shown to be essential in several bacteria. The
eukaryotic and bacterial m1G methyltransferases are structurally dissimilar, making this
enzyme an ideal target for selective anti-TB agents.
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One strategy for TrmD inhibitor design is to target the catalytic center of the
enzyme. Existing inhibitors such as Sinefungin exhibit poor selectivity due to the
substrate’s role, SAM, as a universal methyl donor in many biological processes.
Structure/activity relationships for inhibitory compounds are sparse, impeding the design
of novel antimicrobials. Crystallographic data would identify molecular features unique to
TrmD, and allow design of agents complimentary to the TrmD active site with minimal
differential toxicity. Presently, no crystal structure for Mycobacterium tuberculosis TrmD
exists.

As a first step in this direction, the MtB gene has been cloned and expressed by
using a His-tagged T7 expression vector. The recombinant protein was characterized
through kinetic and preliminary inhibitor assays. The native enzyme displays a mass of 50
kDa, proving this enzyme is a dimer of two identical subunits. This is similar to data found
on other TrmD orthologs. Crystallization of MtB TrmD has been achieved and preliminary
x-ray diffraction studies conducted.

Chapter 1
1.1 General Introduction to Mycobacterium Tuberculosis

Tuberculosis (TB) is the most common cause of infectious disease–related
mortality worldwide. According to the World Health Organization (WHO), one third of the
world's population has been exposed to the tuberculosis pathogen (1). Although TB rates
are decreasing in the United States, the disease is becoming more common in many parts
of the world. In addition, the prevalence of drug-resistant TB is also increasing worldwide.
Co-infection with HIV has been an important factor in the emergence and spread of
resistance (2). New TB treatments are being developed (3) and new TB vaccines are
currently under investigation (4).

Tuberculosis is a communicable disease caused by the Mycobacterium tuberculosis
(MtB) bacterium, which is the causative agent of human tuberculosis. It is an aerobic
bacterium that divides every 16 to 20 hours, an extremely slow rate compared with other
bacteria, which usually divide in less than an hour (5). Humans are the only known
reservoir. The pathogenicity of M. tuberculosis relies on its ability to survive and persist
within the host macrophage cells during infection. The pathogen primarily infects the
mammalian respiratory system but can also attack any part of the body such as the kidney,
spine and brain (5). If not treated properly, TB is fatal. The mode of transmission is
through air from one person to another. A person with active TB disease of the lungs or
throat infects people around them. Two types of conditions exist: latent and active TB. In
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latent, the pathogen lives in one’s body without showing symptoms in the individual. In
active, the person shows symptoms and infects others nearby. Annually, 8 million people
become ill with tuberculosis, and 2 million people die from the disease worldwide. In
2004, approximately 14.6 million people had active TB disease with 9 million new cases.
The annual incidence rate varies from 356 per 100,000 in Africa to 41 per 100,000 in the
Americas (6). Tuberculosis is the world's greatest infectious killer of women of
reproductive age and the leading cause of death among people with HIV/AIDS. It is
responsible for three million deaths annually, more than AIDS, malaria and other tropical
diseases combined. Tuberculosis is one of the three primary diseases of poverty along with
AIDS and malaria (1).
TB was once thought to be virtually eradicated in developed countries due to
development of novel antimycobacterial drugs and improved public health management.
However, the recent resurgence of multi-drug resistant (MDR) strains of TB and the
immunocompromising nature of the HIV virus, which allows TB to thrive and spread in
the host, make the statistics associated with TB frightening. This has led to the WHO
recognizing TB as a potential global emergency for human health. After the discovery of
the first anti-tubercular drug streptomycin in 1943, followed by Isoniazid (INH), ParaAmino Salicyclic Acid and Rifampicin (RIF) in the early 1960s, the drug regime for TB
has remained unchanged for the past 50 years (7). Patients with drug resistance are much
harder to treat. Therefore, it is of importance to identify genes and pathways that are
involved in the survival and persistence of M. tuberculosis within cells. Thus, this indicates
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the urgent need for new anti-TB drugs and subsequent discovery of novel drug targets in
TB.
1.2 Characteristics of Methyltransferases
A methyltransferase (Mtase) is a type of transferase enzyme which transfers a
methyl group from a donor to an acceptor. A considerable number of the methyl groups in
cell metabolites accept a methyl group by an ATP-activated form of methionine, Sadenosyl-L-methionine (AdoMet) (8). Mtases use a
reactive methyl group bound to sulfur in S-adenosyl
methionine as the methyl donor (Figure 1). It is now
known that DNA, RNA, proteins, lipids and
polysaccharides are methylated by AdoMet-dependent
methyltransferases (8).
Figure 1: Structure of AdoMet. Sulfur
bound to methyl group that is donated
to tRNA. AdoMet is highlighted in
yellow.

All types of cellular RNAs contain modified nucleosides, but the largest number
and greatest variety are found in transfer RNAs (tRNAs) (9). tRNAs contain site-specific
base and backbone modifications that are important in overall structural stability and
function (10). One important modification enzyme is the
m1G37 tRNA methyltransferase which methylates the N1
group of guanine at position 37 of tRNA using Sadenosylmethionine (Figure 2). Methylation of G37 requires
Figure 2: Guanine 37 of tRNA
(Anticodon Loop)
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a purine (Guanine) at position 36 of tRNA.
m1G37 tRNA methyltransferase is found in all three domains of life, Eubacteria,
Eukarya and Archaea and is denoted TrmD, Trm5 and aTrm5 respectively (11, 12). This
enzyme is also present in organelles (mitochondria and chloroplasts) and in the bacteria
Mycoplasma spp, which have the smallest genomes known to date (11). Mtase participates
in the translational phase of protein synthesis by maintaining proper codon:anticodon
alignment. Methylation of Guanine at position 37, near the 3’ of the anticodon nucleotides
34, 35, 36, provides a steric hindrance to further Watson-Crick base pairing between tRNA
and mRNA molecules (Figure 3). Thus, it prevents the occurrence of frame shift events
which would result in the formation of truncated or aberrant proteins (13, 14). Hence, it
reduces frame shift errors during translation. Previous experiments have proven this is an
essential function step for yeast and gram negative bacteria (15-17). Studies performed by
Björk et al. (11, 14, 15) reported that the TrmD protein plays a vital role in maintaining the
proper reading frame during translation. Having either a mutant enzyme or trmD gene
knockout will cause the bacteria to grow
more slowly or even be lethal in some
organisms (17). The importance of the
a.

b.

m1G37 modification in the overall
quality of protein synthesis emphasizes

Figure 3: Watson-Crick base pairing. A.) Nucleotides
are base pairing with each other. B.) Nucleotides cannot
base pair due to methylation.

its conservation throughout evolution.
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1.3 TrmD Structure
trmD is a member of the SPOUT methyltransferases which are a class of Sadenosylmethionine dependent enzymes characterized by an unusual α/β fold with a deep
topological knot (18,19). This knot constitutes a major portion of the AdoMet binding
pocket and is buried deep in the protein. Most S-adenosylmethionine dependent
methyltransferases, including trmD, belong to the Class I family which contains the
recognized AdoMet binding pocket known as the Rossman fold (20). Substrates for Class I
methyltransferases include DNA, RNA, small molecules and other proteins (21).
The Holmes laboratory has performed extensive studies on the E. Coli TrmD and
the structure has a 38% sequence homology identity to Mycobacterium tuberculosis trmD
(Table 1). Thus, it will be used as a form of comparison to Mycobacterium tuberculosis
trmD. X-ray crystallography of the E. Coli enzyme reveals two binding sites for AdoMet
which are deeply buried within the interior of the enzyme (22). The E. coli monomer of
trmD consists of two discrete domains, the C-terminal domain and the AdoMet binding
domain, connected by an extended flexible linker region of 11 residues (Figure 4). Five
major parallel beta strands and a sixth short strand extending the sheet on one edge are
inserted between layers of helices and make up the core of the domain (Figure 5). The
AdoMet binding site is found at one end of the beta sheet and is a central part of a deep
trefoil knot structure. Beta sheets are built from a central N-terminal (NT) beta strand β1,
with β2 lying along side of β1, and β4 as the next strand in the sheet which are parallel to
each other (Figure 5). More than one-half of the enzyme is involved in the knot structure,
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which forms the AdoMet-binding site or active site (22). The active site is located in the
AdoMet Domain near the β3, β5 and α5 strands. The active site is located in between the N
and C terminal domains of two monomers. This observation suggests that the dimer edges
interact (22). The substrate, AdoMet, is encircled in a deep pocket surrounded by the
adenine-binding loop, the β3 and β5 strand, and the loop leading into helix α5 (Figure 5).
The loop structure called “the halo” extends between α3 and α5. The C-terminal domain
(CT) consists of alpha coils (α7- α10) connected to the AdoMet domain by a flexible linker
(Figure 5). The substrate takes into a bent conformation in the binding site. The adenine
binding region curves around the adenine ring (Figure 5).

E. coli structure analysis

suggests that significant conformational changes must occur for the substrate binding and
catalytic turnover (22).
Using a program entitled Chimera®, depictions of the active site interacting with
AdoMet was generated. At first glance, certain amino acids appear to interact through
hydrogen-bonds with the AdoMet substrate. The amino acids involved include Tyrosine
134, Glycine 136, Leucine 138, Glycine 140, Glycine 141, Tyrosine 86 and Leucine 87.
Hydrogen bonds between Glycine 134, Tyrosine 136 and Leucine 138 to the AdoMet
substrate help to stabilize the cofactor in place. Additionally, Glycine 140, Tyrosine 86 and
Leucine 87 interact with the ribose of AdoMet to tether it in place (Figure 6). The ribose
moiety of the AdoMet twists in a conformation that results in the methionine region that is
perpendicular to the adenine ring.
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Figure 4: Model of E. coli TrmD (pdb 1P9P) generated by Chimera® displaying dimer
structure with AdoMet domain, C-terminal domain, AdoMet binding site, Adenine binding
loop and Halo region. Homologous monomers are indicated in red and blue ribbons. The
substrate, AdoMet, is represented by red ball & stick structures in each monomer.
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AdoMet

Figure 5: Model of a monomer of E. coli TrmD (pdb 1P9P) generated by Chimera®
displaying monomer structure with alpha 1-10 and beta 1-5 strands, AdoMet and Cterminal domains (CT), AdoMet molecule bound, flexible linker region and Halo region.
NT stands for the N-terminal domain. AdoMet molecule is represented by gray spheres.
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Figure 6: Interaction of amino acids in active site with AdoMet colored green. Pink lines
indicate where hydrogen bonding occurs between amino acids. Image produced using
Chimera®.
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Currently, six crystallographic TrmD protein structures have been done. These
structures correspond to: Anaplasma phagocytophilum, Aquifex aeolicus, Bartonella
henselae, Escherichia coli, Haemophilus influenza and Staphylococcus aureus. An amino
acid sequence alignment between these organisms and Mycobacterium tuberculosis TrmD
was performed using a program entitled “Clustalw” (Figure 7). From this alignment
percent sequence homologies were calculated between the organisms and Mycobacterium
tuberculosis TrmD (Table 1). Bartonella henselae TrmD has a 42.9% sequence homology
to Mycobacterium tuberculosis TrmD, which is the highest percent sequence homology.
Anaplasma phagocytophilum TrmD has a 42.7% sequence homology. Aquifex aeolicus
TrmD has the lowest sequence homology with a 32.6%. Escherichia coli TrmD has a
sequence homology of 38% (Table 1). Sequence alignment of TrmD proteins of known
structures indicates that TrmD from B. henselae and A. phagocytophilum have the highest
shared sequence identity with MtB TrmD. Furthermore, B. henselae contains structural
regions that were overlapping with MtB TrmD and that were not resolved in the other
crystal structures. The length of the B. henselae TrmD (233 amino acids) is almost
identical to the M. tuberculosis TrmD (230 amino acids). Thus, the B. henselaet TrmD is
the best choice for the phasing model, since it includes most of the protein, and has a high
percent homology with M. tuberculosis TrmD. A multiple alignment TrmD diaphragm was
generated using Chimera with Anaplasma phagocytophilum (yellow), Bartonella henselae
(olive green), Escherichia coli (purple), Haemophilus influenza (blue) and Staphylococcus
aureus (orange) (Figure 8). The flexible linker region is yet to be resolved in the pdb
structures.
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Bartonella
Anaplasma
trmDz
E.Coli
Influenzae
StaphAureus
Aquifex

-----------------SMKFQAR--------VLTLYPEMFPGFLGCSLAGQALKQGIWS
-----------------TLEAQTQGPGSMIFNVLTIFPQMFPGPLGVSNLGSALKKGLWT
--------------------MRID--------IVTIFPACLD-PLRQSLPGKAIESGLVD
--------------------MWIG--------IISLFPEMFRAITDYGVTGRAVKNGLLS
----------SSGLVPRGSHMWIG--------VISLFPEMFKAITEFGVTGRAVKHNLLK
----------SSGVDLGTENLYFQSN-AMKIDYLTLFPEMFDGVLNHSIMKRAQENNKLQ
---------------MSSNPLRFF--------VLTIFPHIISCYSEYGIVKQAIKKGKVE
::::* :
.
* : .

35
53
31
32
52
56
37

Bartonella
Anaplasma
trmDz
E.Coli
Influenzae
StaphAureus
Aquifex

LETVQIRDFALDKHHSVDDTPAGGGAGMVMRADVLAAALDSCPNDSP----RLLMSPRGR
LNVFDIRAFANNKHNTVDDTPYGGGPGMLLRADVLGRCIDEVLSLHPN-TKLMFTSPRGV
LNVHDLRRWTHDVHHSVDDAPYGGGPGMVMKAPVWGEALDEICSSET---LLIVPTPAGV
IQSWSPRDFTHDRHRTVDDRPYGGGPGMLMMVQPLRDAIHAAKAAAGEGAKVIYLSPQGR
VECWNPRDFTFDKHKTVDDRPYGGGPGMLMMVQPLRDAIHTAKAAAGEGAKVIYLSPQGR
INTVNFRDYAINKHNQVDDYPYGGGQGMVLKPEPVFNAMEDLDVTEQA--RVILMCPQGE
VYPIDLREFAP--KGQVDDVPYGGLPGMVLKPEPIYEAYDYVVENYGK-PFVLITEPWGE
:
. * ::
: *** * ** **::
. .
:
* *

91
112
88
92
112
114
94

Bartonella
Anaplasma
trmDz
E.Coli
Influenzae
StaphAureus
Aquifex

LLNQAYARSLARSSGVTLVCGRFEGVDERIIEAR----ELEEVSIGDYILSGGETAALVL
SFTQDIARQTMNFDNITLLCGRFEGIDERVVDFY----KLQEVSIGDYVLSGGELAAMVI
LFTQATAQRWTTESHLVFACGRYEGIDQRVVQDAARRMRVEEVSIGDYVLPGGESAAVVM
KLDQAGVSELATNQKLILVCGRYEGIDERVIQTE----IDEEWSIGDYVLSGGELPAMTL
KLDQGGVTELAQNQKLILVCGRYEGIDERLIQTE----IDEEWSIGDYVLTGGELPAMTL
PFSHQKAVELSKADHIVFICGHYEGYDERIRTHL----VTDEISMGDYVLTGGELPAMTM
KLNQKLVNELSKKERIMIICGRYEGVDERVKKIV-----DMEISLGDFILSGGEIVALAV
: : .
. : : **::** *:*:
* *:**::*.*** *:.:

147
168
148
148
168
170
149

Bartonella
Anaplasma
trmDz
E.Coli
Influenzae
StaphAureus
Aquifex

LDAIVRLLPGVMGNEISAKCESFEN---GLLEHPQYTRPAVFEGRGIPPVLTSGHHKAIA
IDTCVRMVPGVIGNAESLKQESME----GSLEYPQYTRPASWKGMEVPEVLLTGNHGEIE
VEAVLRLLAGVLGNPASHQDDSHSTGLDGLLEGPSYTRPASWRGLDVPEVLLSGDHARIA
IDSVSRFIPGVLGHEASATEDSFAE---GLLDCPHYTRPEVLEGMEVPPVLLSGNHAEIR
IDAVARFIPGVLGKQASAEEDSFAD---GLLDCPHYTRPEVLEGLTVPPVLMSGHHEEIR
TDAIVRLIPGVLGNEQSHQDDSFSD---GLLEFPQYTRPREFKGLTVPDVLLSGNHANID
IDAVSRVLPGVLSEPQSIQEDSFQN---RWLGYPVYTRPREYRGMKVPEELLSGHHKLIE
:: *.:.**:.. *
:*
* * ****
.* :* * :*.* *

204
224
208
205
225
227
206

Bartonella
Anaplasma
trmDz
E.Coli
Influenzae
StaphAureus
Aquifex

NWRQQQAESLTRQRRPDLY-ALYNKNRQKT--------------------KWRRNASLSITAARRPDLLKDRYGENDVE---------------------AWRREVSLQRTRERRPDLS---HPD-------------------------RWRLKQSLGRTWLRRPELLENLALTEEQARLLAEFKTEHAQQQHKHDGMAKWRLKQSLQRTWLRRPELLEGLALTDEQRKLLKEAQAEHNSLEHHHHHH-AWRHEQKLIRTYNKRPDLIEKYPLTNADKQILERYKIGLKKG--------LWKLWHRIENTVKKRPDLIPKDLTELEKDILNSILSGKSFKEWLKEHKHLL
*:
* :**:*

233
253
230
255
274
269
257

Figure 7: Amino Acid Sequence Alignment generated by program ClustalW of Anaplasma
phagocytophilum, Aquifex aeolicus, Bartonella henselae, Escherichia coli, Haemophilus
influenza and Staphylococcus aureus. The amino acids in red depict residues that displayed
no electron densities in the crystal structure, which therefore must be very mobile regions
of the proteins Some regions of these proteins are completely conserved such as the halo
region. “*” means that the residues or nucleotides in that column are identical in all
sequences in the alignment. ":" means that conserved substitutions have been observed. "."
means that semi-conserved substitutions are observed.
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Organism

Percent Sequence Homology

Bartonella henselae

42.9%

Anaplasma phagocytophilum

42.7%

Staphylococcus aureus

39.0%

Escherichia coli

38.0%

Haemophilus influenza

34.3%

Aquifex aeolicus

32.6%

Table 1: Percent Sequence Homology of TmD organisms to Mycobacterium Tuberculosis
TrmD.
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Figure 8: Alignment of TrmD organisms. The flexible linker region is unsolved in the pdb
files. The following organisms are shown: Anaplasma phagocytophilum (yellow),
Bartonella henselae (olive green), Escherichia coli (purple), Haemophilus influenza (blue)
and Staphylococcus aureus (orange). Image produced using Chimera®

22

G (37)
G (36)

Figure 9: tRNA Anti-codon arm and Loop
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1.4 Mechanism of Action
AdoMet dependent methyltransferases catalyze the transfer of the methyl group in
a SN2 type reaction scheme, which allows for only one stereoisomeric product to form due
to formation of a triplet state intermediate (Figure 10). The transfer occurs via a
nucleophilic attack at a sp3 hybridized carbon,
which often requires a general base catalyst,
followed by a thioester transition state, and the
release of the product S-adenosylhomocysteine.
Methylation of the N1 position of guanine is
believed to occur via a deprotonation by a
Figure 10: m1G37 methylation

general base catalyst on the N1 nitrogen. tRNA

(guanonsine-N1) methyltransferase (TrmD) is the product of trmD genes which catalyze
the transfer of the methyl group of AdoMet to the N1 position of guanine 37 adjacent the
anticodon loop (Figure 9). These proteins methylate only transfer RNAs that recognize
codons starting with cytosine, and therefore methylate only tRNA species with guanine at
positions 37 and 36. AdoMet is the product of S-adenosylmethionine synthetase, which
transfers the adenosyl moiety of ATP to the amino acid methionine. After transfer of its
methyl group, AdoMet becomes S-adenosylhomocysteine (AdoHcy). Further metabolism
of the product results in the cleavage of the adenosine moiety to form homocysteine.
Homocysteine can either be recycled or eventually broken down into the amino acid
cysteine within the cell. Methylation of Guanine at position 37, near the 3’ of the anticodon
nucleotides 34, 35, 36, provides a steric hindrance to further Watson-Crick base pairing

24
between tRNA and mRNA molecules (Figure 11). Thus, it prevents the occurrence of
frame shift mutations which would result in the formation of truncated or aberrant proteins
(13, 14). Hence, it reduces frame shift errors during translation.

5’

3’

5’

ANTICODON
LOOP

3’

5’

ANTICODON
LOOP

ANTICODON
LOOP

34 35 36 37

34 35 36 37

anti-codon

3’

34 35 36 37

anti-codon

anti-codon

m 1G37
3’

codon

codon

mRNA
Normal alignment

codon

5’

3’

codon

codon

codon

5’

3’

mRNA
+1 frameshift

codon

codon

codon

5’

mRNA
-1 frameshift

Figure 11: Frame shifting prevented during protein translation

1.5 Inhibition of trmD
One potential target site for TrmD inhibitors is the SAM binding site. The presence
of an inactive compound in the cofactor site will abrogate SAM binding and deprive the
enzyme of its methyl donor. Several inhibitors modeled after SAM have been designed and
evaluated, however these agents have been found to be non-selective. This non-selectivity
is a major drawback because SAM is utilized as a universal methyl donor in many
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biological processes (23); hence inhibition of SAM binding will have broad toxicity.
Furthermore, the structures considered in these studies are not diverse and hence structure
activity relationships are poorly defined as of yet. One strategy to achieve selectivity and
high affinity is through structure based design. However, this requires the crystal structure
of TrmD. Crystallographic data will permit identification of molecular features unique to
TrmD, and thus the design of agents complimentary to the TrmD active site(s). This
strategy can be extended through the use of bisubstrate analogues (24); which bridge
between the SAM and nucleoside sites, affording more features to exploit for modification.
The urgent need to develop new drugs due stems from the fact that resistance to
antibacterial drugs is becoming more common. Drug design strategies currently underway
to inhibit tRNA methyltransferase include making analogues of SAM or targeting the
SAM binding site. In a study performed by Barchas and Deguchi (25) it was found that Sadenosyl-L-homocysteine (L-SAH), analogue of SAM, is a potent inhibitor of several
methyltransferases including tRNA methyltransferase (26). This demethylated product
inhibits many SAM-dependent methyltransferases (27). Analogues of AdoMet that either
compete with substrate and/or prevent methylation can be a possible way to inactivate the
enzyme. Mechanism based inhibition that targets the active site of SAM can perhaps
irreversibly degrade the enzyme. Successful DNA methyltransferase inhibitors have been
found. Azacitidine, an approved DNA methyltransferase inhibitor, has also been found to
inhibit RNA and protein methyltransferases (28). This drug acts by incorporating itself into
DNA and preventing methylation by the methyltranferase. Subsequently, cell death is
induced since DNA synthesis is obstructed (28).
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Selectivity is the main challenge in developing inhibitors for methyltransferases.
SAM is a universal methyl donor recognized by many biological processes. Developing a
compound that only targets TrmD is the major hurdle to overcome. Additionally in
understanding mechanisms based inhibition, crystallographic structures of enzymes need
to be determined. Drug potency is also another issue to consider. Yet, the benefit of
designing a drug that effectively targets proliferation of a disease has extraordinary
implications. One third of the world’s population infected with TB will be dramatically
impacted. A successful RNA MTase inhibitor may also affect DNA and protein Mtase.
Furthermore, selectivity over mechanistically similar enzymes can be achieved using the
crystallographic data to tune the drug to the TrmD active site.

1.6 Introduction to Enzyme Kinetics

To determine the maximum rate of an enzyme-mediated reaction, a series of
experiments are carried out with varying substrate concentrations [S]. The MichaelisMenton equation can then be used to determine the constants for the data sets.

The Michaelis-Menten equation relates two observable parameters, the initial
velocity of an enzymatic reaction (Vo) and the substrate concentration [S],
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From the Michaelis-Menton equation it is clear that Vo and [S] do not exist in a
linear relationship. One way to determine Km and Vmax is through the use of a Line-Weaver
Burke plot, in which the 1/Vo is in a linear relationship with 1/[S].

The reciprocals of the experimental parameters V o, [S] may be calculated and a linear fit
performed in which the y intercept is 1/Vmax and the x intercept is -1/Km. This method is
problematic since it represents a linearization of an inherently nonlinear data set. Most
measurements are obtained at high substrate concentrations [S], and hence the data is
clustered around small values of 1/[S]. Thus, a fit is performed over a limited range of
spatially distributed data points. Furthermore, at small values of [S], small errors in V o
propagate into large errors in 1/V o and hence large errors in Km and Vmax. To circumvent
these pitfalls nonlinear regression analysis can be used in which the data is directly fit to a
Michaelis-Menton like equation.
Nonlinear regression is a form of analysis where a function which has nonlinear
parameters, depends on more than one independent variable. This form is best used for
enzyme kinetics due to the problems mentioned above. Actual constants of K m and Vmax
are not determined accurately by the reciprocal Line-Weaver Burke plot. The values for the
slope and intercept are not the most accurate determination of the variables. The program
entitled GraphPad Prism® which uses nonlinear regression analysis determined the
constants for the data sets in these experiments.
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1.7 Introduction to Crystallography
X-ray crystallography provides the most detailed information available on the
structure of molecules. A crystal is mounted between an X-ray source and an X-ray
detector. In an X-ray diffraction experiment, a high quality protein crystal of appropriate
size is mounted on a goniometer. An x-ray source emits a directed beam of x-rays which
bombard the crystal. The x-rays pass through the crystal however they are deflected in the
process. These scattered x-rays are then recorded as a diffraction pattern on an imaging
plate or detector. The crystal is rotated on the goniometer and this process is repeated.
Using the angles and intensities of these diffracted beams, a crystallographer can produce a
three-dimensional picture of the density of electrons within the crystal (Figure 12).
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Figure 12: General Schematic of X-Ray Crystallography
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In an x-ray scattering experiment, a single diffraction pattern is insufficient to
determine a crystal structure. The crystal must be rotated 360 degrees with an image
recorded at several intermediate steps to get enough data to solve the structure. There are
only certain crystallographic planes from which constructive interference leads to strong
diffraction. Each of these planes provides a distinct set of data regarding spatial
arrangement of atoms in the crystal. Furthermore, every diffraction pattern corresponds to
a different image of the electron density map and each spot in the diffraction pattern
corresponds to a different type of variation in the electron density. The electron density
maps are related to diffraction data by a Fourier transform.
A Fourier transform is used to find the electron density from the diffraction pattern.
This transform takes as input structure factors for each spot and their corresponding
frequencies. The structure factor is proportional to the square root of the measured spot
intensity and the frequency corresponds to the location of the spot in the diffraction
pattern. Unfortunately, only the absolute value is available. Hence, additional information
is necessary to determine phases and thus electron density maps. The following are
common ways to solve the phasing problem of crystallography: Heavy Element
Replacement, Anomalous Dispersion, Molecular Replacement (29).
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1.8 Specific Aims of the Research

A.) To clone and characterize Mycobacterium Tuberculosis trmD gene.
We will clone the trmD from Escherichia coli into an appropriate expression
vector. Protein made in this vector will display an added N terminal his tag sequence
permitting rapid purification of recombinant protein using Ni affinity column technology.
To establish that the cloned gene product is in fact a tRNA methyl transferase, synthetic
tRNA1Leu substrate which contains G37 and G36 residues in the molecule will be
employed. It has been shown previously that this serves as a substrate for several TrmD
proteins. This will involve the determination of Km and Vmax values at various
concentrations of both S-adenosyl methione and tRNA. We will be able to compare these
values to that of other orthologues of TrmD.
Once protein is obtained and shown to be a bona fide TrmD methyltransferase, we
will first determine its oligomeric structure and demonstrate whether or not it will exist in
solution as a homodimer. All other TrmD proteins so far obtained have been shown to be
dimeric (22).

B.) To Crystallize Mycobacterial TrmD protein, and ultimately obtain the
crystal structure. Initial crystal screens will be done using Hampton® general screening
kits. If crystals are obtained, conditions will be optimized and diffraction studies will be
carried out in collaboration with Dr. Martin Safo. Once diffraction data is obtained of
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sufficient resolution, attempts to solve the structure will be carried out using Molecular
replacement programs available to us.
C.) Ultimately, if a structure is obtained attempts to develop inhibitors of the
enzyme will be initiated. This however, maybe beyond the scope of this study, but
certainly a structure will facilitate this effort for rational drug design. In addition, with the
protein in hand, other high throughput screens for inhibitors could be carried out.

Chapter 2: Materials & Methods
Materials:
The Novagen ligation-independent cloning vector was used for cloning and
expression of M. tuberculosis gene DNA into suitable Eschericha Coli host cells. The
oligonucleotides necessary for PCR amplification of trmD sequences were ordered from
Integrated DNA Technologies ®. Using these oligonucleotides, Finnzymes Phusion HighFidelity Polymerase Chain Reaction (PCR) Master Mix® was used to amplify the desired
trmD sequence from genomic DNA. QIAquick® Gel Extraction Kit was utilized to purify
DNA from the agarose gels used to isolate amplified gene sequences. Ampicillin was
obtained from Sigma® and isopropyl β-d-thiogalactopyranoside (IPTG) was obtained from
Molecula®. LB broth growth media was purchased from Fisher and Sigma®. NovaBlue
GigaSingles Competent Cells were purchased from Novagen®. Plasmid DNA was purified
using the QIAprep Miniprep® kit was ordered from Qiagen. The DNA Core laboratory
3700xl machine for sequencing located in Sanger Hall, MCV campus was utilized.
Sonication was used to disrupt cells at a small scale and French Press was used for larger
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preparations. Microcolumn® Nickel-NTA columns were used for the pilot scale batch of
protein.
Methods:
2.1 Cloning
The trmD gene from Mycobacterium tuberculosis was isolated from genomic DNA
of the MtB CDC1551 strain (gene ID 925304/ accession number is NP_337486.1). This
was provided to us by the laboratory of Dr. John Hackett. The pET46 EK/LIC ligationindependent cloning system was utilized for cloning (Novagen®) (Figure 13a). Ligationindependent cloning (LIC) exploits the 3’ to 5’ exonuclease activity of T4 DNA
polymerase to strip nucleotides from a specific gene. This process continues until the
polymerase utilizes and inserts a single dATP, which has been included in the reaction
mixture. At this point, the polymerase activity of the enzyme overrides the exonuclease
activity terminating the excision process and thus providing long sticky ends
complementary to the overhangs in the LIC vector (Figure 13b). The resulting nucleic acid
is readily introduced into the vector through a short annealing step, circumventing the
ligation process. The pET46 vector contains an N-terminal His-tag expresses protein under
the control of the T7lac promoter. Since the host cell contains an inducible RNA
polymerase gene, and a lac operator, repressor system, IPTG addition leads to expression
of the trmD gene. Furthermore, this vector contains kanamycin and ampicillin resistance
genes for selection of transformed cultures.
Forward and reverse primers were specifically designed for expression using
Novagen’s EK/LIC system. To ensure optimal function, primers were chosen which have
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an absence of dimerization capability and avoid primer self-complementarity which may
result in secondary structure formation. The following properties were used when
designing the primers: 17-28 bases in length, Tm between 55-65°C, absence of
dimerization capability (avoid primer self-complementarity which form secondary
structures), and should have a 50-60% GC rich base ration (23). The designed primers are
as follows:
UPSTREAM:

5’-GACGACGACAAGATGCGCATCGATATCGTGACGATCTTC-3’

DOWNSTREAM:

5’-GAGGAGAAGCCCGGTCTAGTCGGGGTGGGACAG-3’

Amplification was performed using the Phusion High-Fidelity Polymerase Chain
Reaction (PCR) Master Mix (New England BioLabs). Following PCR amplification, the
DNA was purified on an agarose gel and extracted using an alkaline ethanol method via
the QIAquick® Gel Extraction Kit. 700 base pair bands were clearly detectable in
duplicate wells as judged by DNA standards. These DNA bands were next treated with T4
DNA polymerase, which exposes single stranded complementary sequences.
The isolated DNA fragment was annealed with the pET-46 vector (Figure 13a)
which comes with exposed complementary strands. Next the mixture of vector and insert
was mixed with competent NovaBlue GigaSingle® cells. NovaBlue is an E. coli K-12
strain and has high transformation efficiency with blue-white screening capability and recA
endA mutations. Cells were provided in a 50 μl single-use volume tube and stored at 70°C. Consequently, 250 μl of SOC media, provided in the kit, was added to the
GigaSingle tubes. The tubes were incubated at 37°C while shaking at 250 rpm for 60
minutes prior to plating on ampicillin medium. Selection for transformants was carried out
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by plating cells mixed with vector and annealed insert on agar plates containing 50 μg/ml
ampicillin. Plates were set on the bench for several minutes to allow excess liquid to be
absorbed, inverted and incubated overnight at 37°C. Ten transformant colonies were
picked from the agar plate and using a sterile toothpick and each were transferred to a 0.5ml eppendorf tube containing 50 μl sterile water and vortexed to disperse the cells. All
tubes were placed in boiling water to lyse cells and denature DNAases, then centrifuged at
12,000 x g for 1 minute to remove cell debris.
A PCR reaction mixture was setup using PCR-grade water, dNTPs, upstream
primer, downstream primer, 10X NovaTaq Buffer with MgCl2 and NovaTaq DNA
Polymerase. Positive and negative controls were also included in the procedure. The cycles
for PCR were repeated 35 times for the purpose of amplifying the plasmid. An agarose gel
was made including DNA from all 10 clones isolated, a positive control and negative
control and one well for the DNA 100 base pair ladder. Phusion High-Fidelity Polymerase
Chain Reaction (PCR) Master Mix was used to make a PCR product. PCR conditions
included: initial denaturation at 98°C for 30 seconds, denaturation at 98ºC for 10 seconds,
annealing at 70°C for 30 seconds and final extension at 72°C for 10 minutes. The
denaturation and annealing step continued for 35 cycles. The sample was then put into a
1% agarose gel 1X TAE. QIAquick Gel Extraction Kit® using a microcentrifuge was used
to separate purified DNA from agarose gel.
Next, DNA containing inserts as judged by analysis via gel electophoresis was
purified and sent to the VCU DNA Core facility. Appropriate clones were inoculated in
Luria Broth (LB) and grown for 5 hours at 37°C.

After this time, the tubes were
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transferred to large tubes and centrifuged for 5 minutes. The liquid was discarded and the
cell pellet was left intact. The QIAprep Miniprep® extraction kit was utilized to extract
DNA from the LB media in a matrix band tube. Four DNA samples and the appropriate
complementary DNA primers were sequenced at the DNA Core laboratory. DNA was
sequenced using a 3700xl DNA Analyzer. The concentration of DNA utilized for
sequencing was 100 μg/ml, and the concentration of DNA reverse and forward primers
were 20 μg/ml. T7 polymerase for chain elongation and reagents for dideoxy sequencing
reactions was provided by the Core laboratory. Data were sent via email as ASCII
sequence files or raw data. Sequence Scanner® was used to view the electropherograms
and the Expasy® website was used to compare the sequences.
2.2 Expression
Initially, a small scale culture was processed to determine if any protein was being
made by the selected constructs. Recombinant DNA from several clones were each
transformed into Rosetta RS2 cells. These host cells provide rare tRNA species which
might recognize rare codons in the cloned trmD gene DNA. Each transformation mixture
was plated with chloramphenicol and ampicillin for positive selection. Chloramphenicol is
added to maintain the second plasmid in the Rosetta strain which encodes the rare tRNA
species. Ampicillin selects for the recombinant plasmid containing the trmD gene. The
plates were incubated overnight at 37°C. Isolated colonies were selected from plates and
each inoculated into LB test tubes. The tubes were then incubated at 37°C for 3-4 hours in
a rotary shaker (200 rpm). These tubes were added to 4 ml of LB media and inoculated for
1 hour. Spectrophotometer readings were periodically taken until OD reading of 0.6 (at
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600 nm) was achieved. The cells were then induced with 1mM IPTG and shaken in a
rotary shaker (200 rpm) overnight at 18°C. Cells were harvested by centrifugation for 10
minutes at 10,000 rpm at 4°C. The cell pellets were suspended in resuspension or lysis
buffer (300mM NaCl, 50mM pH 7.5 phosphate buffer, 10 % glycerol and 10mM
Imidazole). Cells were disrupted using an Avestin Multiflex® cell disrupter. In all cases
three passes through this automated French Press were carried out. Cell debris was then
removed by centrifugation of the crude extract for 30 minutes at 15,000 rpm. The soluble
supernatant was collected and microcolumn Nickel-NTA columns from Qiagen® were
used for purification. Centrifugation and equilibration of extract through these commercial
spin columns (6000 rpm for 1 minute) assisted in separating protein from cells. The
columns were washed with 300mM NaCl, 50mM pH 7.5 phosphate buffer and 10mM
imidazole. Protein was eluted with 300mM Imidazole, 10 mM NaCl and 50mM pH 7.5
phosphate. An SDS (Sodium dodecylsulfate) PAGE gel was done to check for the presence
of protein.
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Figure 13a: pET-46 Ek/LIC Vector generated by program EZ PLASMID MAP V1.9®.
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Figure 13b: Diagram of Ek/LIC strategy (Adapted from Novagen®)
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2.3 Protein Purification
Large scale protein expression was next performed. Each liter of culture broth was
prepared by adding 25 grams of granular LB-Broth from Fisher to 1 liter of deionized
water. After the media was autoclaved, ampicillin was added at a concentration of 50ug/ml
and chloramphicol at a concentration of 25μg/ml. These were added because the E.coli
BL-21 strain contains the pET-46 vector, which in turn has the Mycobacterium
tuberculosis trmD gene and the ampicillin and the Rossetta strain contains the tRNA
encoding plasmid selected and maintained in the stain by chloramphenicol resistance. The
culture medium was then inoculated with an overnight 30 ml starter culture containing
ampicillin and chloramphenicol. Four liters of media were grown to obtain protein. Cells
were put in a shaker at 200 rpm at 37oC. Cultures were grown to an A600 of 0.6, then
induced over night at with 1 mM isopropyl β-D-thiogalactopyranoside (IPTG) at 180C.
Cells were harvested by centrifugation at 5,000 rpm and the pellet was resuspended in lysis
buffer, which contained 300mM NaCl, 50mM pH 7.5 phosphate buffer and 10mM
Imidazole. Cells were then frozen at -80oC for subsequent protein isolation and
purification.
The cells were then lysed using the Avestin French Press machine at 20,000 psi. In
all cases extracts were passed three times through the cell disruptor. Consequently, the
crude cellular lysate was centrifuged for 30 minutes at a speed of 10,000 rpm. The crude
extract was then loaded onto a Qiagen® Ni-NTA nickel column. TrmDz protein has a Histag that is therefore bound tightly by the Nickel-NTA agarose beads. Wash buffer was then
passed through the column, which contains 300mM NaCl, 50mM pH 7.5 phosphate buffer
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and 10mM imidazole. This step was performed to remove any non specific binding protein
as judged by removal of all detectable OD from the column. Following this initial wash,
TrmD protein was eluted from the column with elution buffer containing a high
concentration of imidazole. Elution buffer contains 300mM Imidazole, 10 mM NaCl and
50mM pH 7.5 phosphate. Washing and eluting protocols using gravity flow as outlined by
Qiagen® were modified as follows: after extensive washing in buffer A, the column was
washed in a buffer with lower salt (50mM phosphate buffer pH 7.5, 50mM NaCl, 250mM
imidizol). Fractions were collected and protein concentration was estimated by measuring
UV absorbance at 280nm. Peak fractions were pooled and analyzed for purity via SDS
PAGE gels. Next the samples were dialyzed overnight in (50mM Tris-HCl pH 7.5, 300
mM NaCl, 5mM 2-mercaptoethanol, .5mM EDTA, and .04% Na-Azide) in the cold room.

2.4 SDS Polyacrylamide Gel Electrophoresis (SDS Page)
The SDS Page gel was prepared following the protocol generated by Laemmli (30).
This gel has a 12.5% acrylamide separating gel and a 4.1 % stacking gel. A gel is
generated with a 10x10 cm gel rack with a thickness of 0.75mm. The protein samples to
be analyzed are prepared by first adding appropriate amounts of 2X SDS loading buffer,
which is made up of Tris buffer, SDS, glycerol and the reducing agent beta
mercapoethanol, to the protein solution containing about 10-100μg protein. Then the
protein was denatured by placing the samples into boiling water for 2-5 minutes. The SDS
PAGE running buffer contained Tris-base, glycine and SDS.

One liter of 5X stock

solution of the protein running buffer contains 15 grams of tris-base, 72 grams of glycine
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and 5 grams of SDS. A 1X solution of this mixture is used to perform SDS Polyacrylamide
Gel Electrophoresis. Approximately 15μl of sample solution was loaded into each well,
then electrophorized at a constant voltage of ~50mV at room temperature. The 2X loading
buffer contains bromophenyl blue, which determines the progress of electrophoresis. As
soon as this dye reached the bottom of the gel, electrophoresis was stopped. Gels were
then stained with coomassie brilliant blue solution, containing 50% H20, 40% methanol
10% acetic acid and (v/v) 0.05% coomassie brilliant blue R250, ideally it is allowed to sit
over night and subsequently destained with a destaining solution composed of 70% water,
20% methanol and 10% acetic acid.

2.5

Native Gel Electrophoresis

"Native" or "non-denaturing" gel electrophoresis was performed in the absence of
SDS. In the SDS-PAGE the electrophoresis mobility of proteins depends primarily on their
molecular mass, however in the native PAGE gels mobility depends on both the protein's
charge and its hydrodynamic size. The resolving gel contained 10% acrylamide and Bisacyalimde added to achieve a ratio of 1:37 and .4M Tris-HCl pH 8.8. The stacking gel
contained 7.5% acylamide and Bis-acrylamide was added to achieve a ratio of 1:37 and
0.25M Tris-HCl pH 6.8. Polymerization of gel was achieved by the addition of 10ul of
Tetramethylethylenediamine (TEMED) and 40ul of 15% ammonium persulfate. Sample
buffer contained 100mM Tris-HCl buffer pH=6.8, 200 mM DTT, 20% glycerol and .1%
bromophenol blue. The electrophoresis buffer contained 3g of Tris base and 14.4 grams of
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glycine in one liter. The final pH was 8.3. Protein stain solution consisted of .05%
Coomassie Brilliant Blue R, 50% Methanol, 40% water and 10% Acetic Acid (v/v).
Destaining solution contains 50% Methanol, 40% water and 10% Acetic Acid (v/v).

2.6 Methods of Kinetic Assays
Two assays were developed to assess TrmD kinetics as well as inhibition. In the
process of performing a kinetic assay, the velocity of the reaction is measured at a series of
incrementally increasing substrate concentrations. This permits determination of Km and
Vmax. For these assays, the concentration of enzyme and cofactor were optimized. In the
case of TrmD, the substrates are a G36G37 tRNA (tRNA1Leu) and S-adenosyl-methionine
(AdoMet). Enzyme activity was determined using a modification of the method developed
by Hjalmarsson et al. (31). The assay conditions were optimized to ensure proper function
of the enzyme for the measurements conducted. 50 µl of reaction mixture consisted of 50
µM cold SAM, 1.8 µl of 3H-SAM (specific activity 85 Ci/mmol), buffer (0.1 M Tris-HCl
pH 8.5, 1 mM DTT, 0.1 mM EDTA, 6mM MgCl 2, 24 mM NH4Cl, 20 µg of enzyme and
variable amounts of E. coli tRNA1Leu transcripts (Figure 14). Using these conditions as a
starting point the parameters were optimized for the MtB TrmD. tRNA synthesis was
performed using a combination of methods. The protocol described in Holmes et al. (32)
outlined a basis for the procedure. Template preparation involved the growth of pUTL4 in
XL1-Blue E. coli cells obtained from Stragene. Plasmid purification was carried out using
the Qiagen Plasmid Giga kit® followed by DEAE batch column chromatography. Using
these methods tRNA was produced and supplied by M. Palesis.
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To ascertain an optimal enzyme concentration for the assay, tRNA and AdoMet
concentrations were added in excess and the enzyme concentration varied. Activity was
measured in a time course spanning 25 minutes in a 5 minute interval. Once an optimal
enzyme concentration which ensured linear methylation over the time course of the assay
(20 µg of protein per assay), a second series of experiments were performed in which the
concentration of SAM was varied in the presence of excess tRNA concentration to allow
determination of Km and Vmax for SAM. The concentrations of SAM employed were 45
µM, 65 µM, 150 µM, 155 µM. 5 minute assays were carried out. The values of [tRNA]
were 5 µM, 15 µM, 18 µM, 58 µM, 78 µM and 65 µM set through a time course assay of 5
minute intervals between concentrations. The enzyme reaction was allowed to proceed for
4 minutes. Following 4 minutes, the reaction was stopped by adding 1 ml of ice cold (10%)
tri-chloro-acetic acid (TCA). After 15 minutes, all of the tRNA is completely precipitated,
and the reaction mixture is loaded onto a GF-A Whatman filter paper. Vacuum filtration
and washing with TCA was done to remove excess labeled free AdoMet. The filter paper is
then dried with 100% ethanol and activity is measured (Figure 14). The filter paper will
retain the radioactively labeled tRNA which then can be counted using the Packard TriCarb 1500 Liquid Scintillation Analyzer. Conversely, to obtain the Km and Vmax for the
tRNA excess SAM and the tRNA concentration varied. The time course of the reaction
was followed to ensure the rate being observed in these assays was linear and
representative of the initial reaction rate. Km and Vmax were calculated by using the
program Prism® which utilizes non-linear regression analysis.
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A preliminary inhibitory assay was also conducted on this enzyme. The same
procedure as clone for the kinetic assays was utilized (Figure 14) except that 156 uM of
inhibitory compounds were included in the reaction mixture. The two inhibitory
compounds used were Congo Red and 4,4'-bis(1-anilinonaphthalene 8-sulfonate) (BisANS) (Figure 16). Both these compounds are hydrophobic and have proven to be
inhibitors of the E. coli TrmD protein (unpublished, M Palesis).
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Figure 14: General Schematic for the kinetic assay reactions performed for varying
substrate concentration
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a.

Figure 15: Structure of Inhibitors
a.- Congo Red
b.- 4,4'-bis(1-anilinonaphthalene 8sulfonate) or Bis-ANS

b.

2.7 Methods of Crystallography
The most common setup to grow protein crystals is by the hanging drop technique.
A few microliters of protein solution are mixed with an about equal amount of reservoir
solution containing the precipitants. A drop of this mixture is put on a glass slide which
covers the reservoir. As the protein/precipitant mixture in the drop is less concentrated than
the reservoir solution (protein solution with the reservior solution about 1:1), water
evaporates from the drop into the reservoir. As a result the concentration of both protein
and precipitant in the drop slowly increases, and crystals may form (Figure 16). Simply
put, the hanging drop method differs from the sitting drop method in the vertical
orientation of the protein solution drop within the system. It is important to mention that
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both methods require a closed system, that is, the system must be sealed off from the
outside using an airtight container or high-vacuum grease between glass surfaces (Figure
17). Even smaller volumes can be handles in button-like dialysis cells which are often used
in x-ray crystallography. A dialysis membrane with a cutoff molecular weight value is
used to seal the buttons. However, it is important that the buttons are completely filled and
without air bubbles which otherwise can prevent the contact of the solution with the
dialysis membrane.

Figure 16: Hanging Drop Diagram
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Figure 17: Sitting Drop Diagram

A seed provides a template for the assembly of molecules to form a crystal with the
same characteristics as the crystal from which it originated. It is important to differentiate
the process of crystal growth from nucleation. In general, the degree of supersaturation
required for nucleation is higher than that required for crystal growth. Normally, during
aggregation, there is an equilibrium between the formation of ordered nuclei (reversible)
and the formation of fprecipitate (irreversible). When crystal seeds are added, the
equilibrium can shift towards crystal formation, and avoids the random nature of
spontaneous nucleation. There are three commonly used types of seeding: Microseeding
which adds very small pieces of crushed protein crystals to the crystallization drop;
Macroseeding which adds an intact, already grown crystal to the crystallization drop;
Streak seeding which is similar to microseeding but uses a fine hair (often a cat’s whisker
or horse hair is best) to pick up small protein crystal fragments.
Mounting of most protein crystals on an x-ray diffractometer is done at cryogenic
temperatures, usually around 100K. A small nylon loop is used to pick up a crystal,

49
immerse it a cryoprotectant solution for a short period of time, and then either plunge it in
liquid nitrogen (or sometimes liquid propane), or place it directly on the goniometer head
in a stream of cold nitrogen gas.
Crystals of M. Tuberculosis TrmDz without AdoMet bound grew in sitting drop
trays at 25°C at room temperature. The concentration of the protein was 12.4 mg/ml in 50
mM Tris-HCl pH 7.5, 0.1 M NaCl, 1 mM DTT. Drops were a 2ul:2ul ratio mixture of
protein to precipitant. Hampton Research Crystal Screening 1 was used to screen reagents.
A total of 48 reagents were included in the kit. The 24 well VDX48 crystal trays with
sealant from Hampton Research were utilized for the screens. Siliconized Glass Cover
Slides from Hampton Research allowed a droplet to be suspended in a position which
provides near optimal conditions for vapor diffusion. The cryoprotectant used was 25%
glycerol for each crystal shot.
Initially, attempts to crystallize the

M. Tuberculosis TrmD protein were done

without AdoMet in sitting drop trays at 25°C. The concentration of the protein usedwas
12.4 mg/ml in 50 mM Tris-HCl pH 7.5, 0.1 M NaCl, 1 mM DTT. Each Drop contained
2μl of precipitant and 2 μl

of protein solution. Initially, Hampton Research Crystal

Screening kit 1® was used to screen reagents. This kit provided 48 separate precipitant
solutions. Hampton Research® (24 well) VDX48 crystal trays with sealant were utilized
for the screens. Siliconized glass cover Slides from Hampton Research were employed as
well. Most of the following steps were carried out with the help Dr. Martin Safo in the
Institute. In all cases promising crystals from selected wells were suspended in 25%
glycerol plus the correct selected precipitant.
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Diffraction experiments were performed on a Raxis IV (Rigaku Americas Co.)
diffractometer under Nitrogen cryo-cooling conditions at -100 K. Crystals were swiftly
taken out of the mother liquor in the well using a nylon loop then flash-frozen under a
stream of liquid nitrogen on the goniometer head. Indexing of initial frames showed
different forms for buffer conditions. The diffractometer was programmed to collect 0.5°
oscillation frames from φ angles 0° to 180° at 0.5° intervals (360 frames) and an exposure
time of 10 minutes. The crystal-to-dectector distance was adjusted to 130mm. Once the
data collection was complete, the data was integrated using the d*trek program under the
CrystalClear® software package (Rigaku Americas Co). The program entitled CrystalClear collects and integrates the reflection of spots.

Chapter 3
3.1 Results of Cloning
As outlined in the previous section trmD sequences have been cloned and verified
by sequence analysis. Using the protocols and stated in the methods section, forward and
reverse primers were designed then used with a Finnzyme Phusion High-Fidelity PCR
Master Mix® to PCR trmD sequences from genomic DNA. Once PCR was performed,
an agrose gel confirmed the presence of amplified trmD DNA (Figure 18). In figure 18
700 bp bands are seen as judged from a 100 bp DNA ladder which corresponds nicely
with the calculated size of the amplified gene (MW 693). Consequently, the DNA was
extracted and cloned into a pET-46 EK/LIC vector. Once cloned host cells were
transformed as outlined above and ten colonies selected for analysis. DNA extracted from
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each of these clones was analysed by analytical PCR which should determine if trmD
inserts were present. Inserts were found in colony numbers 2, 6, 8, 10 (Figure 19).
DNA was prepared from clones 6 and 8 which had been shown to contain trmD
inserts as judged by PCR amplification. Plasmid DNA from these two clonal isolates was
sent to the DNA Core laboratory for sequencing. The results from the sequencing lab
reported that all sequences were in-frame and contained no mutations. The sequences for
samples 6 and 8 were found in the first frame (Figure 20). These samples were used for
protein expression and named TrmDz1 and TrmDz2, respectively. Utilizing the program
Sequence Scanner v1.0® an actual sequence readout from the 3700 sequencer is shown
(Figure 21).
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BP Ladder

Sample 1 Sample 2

700 BP Band

Figure 18: Agarose gel of PCR product: leftmost lane; 100 base pair (bp) ladder, Sample
and Sample 2. Sample 1 and 2 contained 20ul of PCR product. The red arrow indicates
where the 700 base pair standard runs.
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Figure 19: Agarose Gel electrophoresis of PCR amplified trmD gene inserts.
Left to Right: Molecular Weight standards Ladder (L), 2, 6, 8, 10 and positive control
contained inserts.
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Mycobacterium Tuberculosis trmD CDC1551
Amino Acid Sequence
A. V R I D I V T I F P A C L D P L R Q S L P G K A I E S G L V D L N V H D L R
R W T H D V H H S V D D A P Y G G G P G Met V Met K A P V W G E A L D E I
CSSETLLIVPTPAGVLFTQATAQRWTTESHLVFACGRYE
G I D Q R V V Q D A A R R Met R V E E V S I G D Y V L P G G E S A A V V Met
VEAVLRLLAGVLGNPASHQDDSHSTGLDGLLEGPSYTR
PASWRGLDVPEVLLSGDHARIAAWRREVSLQRTRERRP
D L S H P D Stop
Sample 8 Forward Primer:
B.5'3'Frame1
PACLDPLRQSLPGKAIESGLVDLNVHDLRRWTH DVHHS
V D D A P Y G G G P G Met V Met K A P V W G E A L D E I C S S E T L L I V P
TPAGVLFTQATAQRWTTESHLVFACGRYEGIDQRVVQD
A A R R Met R V E E V S I G D Y V L P G G E S A A V V Met V E A V L R L L A
GVLGNPASHQDDSHSTGLDGLLEGPSYTRPASWRGLDV
P E V L L S G D H A R I A A W R R E V S L Q R T R E R R P D L S H P D Stop T
G L L L K S R V W Stop R N R C C E I Stop T P A H G L V Y Stop R S L I N L G
C C H R Stop A I T S I T P W G L Stop T G L E G F F A E R R N Y I R I G E W D
APCSGALSAAGVVVTRSVTATLASALAPAPFAFFPSFLA
T F A G F P R Q A L N R G L P L G S D L V L Y A L D P K N Stop L G D V T Y G
H R L I D V F A F D V E S T F L I W T L S L T H S P I S I Y P Stop I K E L R I A S
KNGADYKLRD
Figure 20: Sequencing Results a.-putative amino acid sequence for annotated gene, (gene
ID 925304/ accession number is NP_337486.1) b.- Amino acid sequence derived from the
DNA sequence of clone 8. Shown in red is the deduced amino acid sequence from one of
the reading frames of this sequence.

Figure 21: Screenshot of Sample 8 DNA sequence using Sequence Scanner Program®
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3.2 Expression and Purification
Clones 6 and 8 which have been designated TrmDz1 and TmDz2 were expressed at
a pilot scale to determine if protein of the correct size had been made. As can be seen in
Figure 22, protein of the correct size can be seen for both clones 6 and 8. Since this is a
SDS gel then this should reflect the monomer molecular weight of the subunits for this
TrmD protein. A monomer form with a molecular weight of approximately 25 kDa is seen
as judged by molecular weight markers incorporated in the gel. The actual size of the
TrmD protein should be larger than 25 kDa since there is now a His-tag sequence present
at the amino terminus. The gel mobility reflects these added residues.
Since the protein gels displays bands of the correct size from both clones, a larger
scale expression of TrmDz2 was initiated. A two liter volume of cells was induced with 1
mM IPTG once the OD at 600 nm reached 0.8. The liters were incubated in the shaker at
18°C at a speed of 200 rpm overnight.
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CE1 CE2 PC1 PC2 CL1 CL2 PL FT1 FT2 W1 W2 EL1 EL2

25 kDa

Figure 22: Protein Gel of MtB TrmD Sample 1 is TrmDz1 and Sample 2 is TrmDz2.
Order of wells: protein after incubation trmDz1 (Cell Extract 1), protein after incubation
trmDz2 (Cell Extract 2), protein centrifuge trmDz1 (Protein Centrifuge 1), protein
centrifuged trmDz2 (Protein Centrifuged 2), cell lysate z1 (Cell Lysate 1), cell lysate z2
(Cell Lysate 2), protein ladder (Protein Ladder), flow through z1 (Flow Through 1), flow
through z2 (Flow Through 2), wash z1 (W1), wash z2 (W2), elution z1 (EL1), elution z2
(EL2). Arrow points to 25kDa on the Protein Ladder.
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3.3 Protein Purification
As outline above the cultures were centrifuged and the cells lysed using the French
Press. Crude extracts were clarified by centrifugation, then purified using Ni-NTA
columns as outlined above. Figure 24 shows stained proteins in a 12% SDS Acrylamide
gel. In this case BL21(DE3) host cells were used and excellent expression was achieved.
Approximately 9 ml of purified protein was obtained containing 12 mg/ml of TrmD
protein. As can be seen in all appropriate wells. A single band of 25 kDa was observed on
the SDS-PAGE gel (Figure 23).

In these cases, very high levels of TrmD protein were

added (25 μg per well) to show the degree of purity of the protein.
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Figure 23: SDS protein gel of purified Mycobacterial TrmD protein. Lanes from left to
right: Protein Ladder (PL), Cell Lysate (CL1), Protein (P1), and Protein after Dialysis
(D1). Sample CL2, P2 and D2 are repeats of the left side. In the case of purified TrmD
samples approximately 25 μg of TrmD protein were loaded.
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Figure 24: Native Gel with purified MtB TrmD protein concentrations in designate lanes:
Sample 1 (5ug), Sample 2 (4ug), Sample 3 (3ug) and Sample 4 (1 ug). The first well is the
Protein ladder. The bands all line up to the 50 kDa line of the ladder.
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It has been shown that all TrmD protein orthologues so far studied are homodimers
(22). The putative subunit molecular weight of this enzyme was consistent with that of
other TrmD proteins. In order to determine whether or not this enzyme is dimeric like
other TrmD proteins, samples of Mycobacterial trmD protein was electrophoresed through
Polyacrylamide gels without SDS or other denaturants. As shown in figure 24, samples run
show a molecular weight of approximately 50,000 daltons which is consistent with a
dimeric form of the enzyme.
3.4 Results of Kinetic Assays
The Vmax for SAM was .02818 nM product/min/ug of protein and the Km was 26
µM (Figure 26). The methylation kinetics of the tRNA displayed a V max of .001024 nM
product/ min/ µg protein and a Km of 41.80 µM (Figure 27). Extensive kinetic analyses
have been performed on the E. coli TrmD and these results can be compared to that of the
MtB TrmD. Previous data has shown that the E. coli TrmD has a Km value of 5 µM for
tRNA methylation and 8 µM for SAM methylation (32). A turnover number was
calculated and compared with that of MtB TrmD (Table 2). The turnover number was 12.6
molecules of product/molecule of enzyme/minute for E. Coli TrmD and 0.14 molecules of
product/molecule of enzyme/minute for the MtB TrmD. This result reveals that the E. coli
enzyme is much more active than the MtB enzyme. In the inhibition studies, both
compounds at 156 µM proved to significantly diminish the activity of MtB enzyme.
Activity drastically dropped from a 13000 CPM3H to a mere 449 CPM3H for the Bis-ANS
and 330 CPM3H for the Congo Red assays. Thus, these compounds are potent inhibitors
for this enzyme.
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Figure 25: Kinetic Assay Data of enzyme, TrmDz, and varying concentration of substrate,
SAM.
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Figure 26: Kinetic Assay Data of enzyme, TrmDz, and varying concentration of substrate,
tRNA.

Table 2: Table comparing E. coli and MtB TrmD turnovers
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Figure 27: Graph representing activity of enzyme in the presence of inhibitors Bis-ANS
and Congo Red.

3.3 Results of Crystallization
As previously mentioned, all crystals were grown at room temperature. There were
several conditions where crystals were observed. The first was 30% Polyethylene Glycol
(PEG) 4000, 0.1M Tris-HCl, 0.2M Lithium Sulfate (Figure 28 a,b). The protein
concentration was 12.4 mg/ml. Microcrystal showers were observed under this condition
after one week. Optimization of this condition was performed. Larger, better crystals were
never produced.
The second condition which produced crystals was 1.0M Ammonium Phosphate,
0.1M Na Citrate pH 5.6 (Figure 28 c,d). One single crystal formed in this well after three
weeks. A resolution of 4.9 Å was observed for this crystal formation. The spot intensity
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dropped after 7.8 Å. The crystal shape was hexagonal. The unit cell was a=b=119.765 Å,
c=172.29. After optimization of conditions, larger crystals were observed in 0.8M
Ammonium Phosphate 0.1 M Na Citrate pH= 5.6 and 0.9M Ammonium Phosphate 0.1M
Na Citrate pH=5.6 (Figure 28 f,g). However, after diffraction it was found that the
resolution was poor for this crystal formation, 3.5 Å (Table 3).
Two other conditions found were 20% Polyethylene Glycol (PEG) 3350 0.2M diAmmonium Citrate and 20% Polyethylene Glycol (PEG) 3350 0.2 M Calcium Acetate
(Figure 28h). However, even after optimization larger crystals were not produced.
The best condition for growth was 1.2M Sodium Formate, 0.1M Na Acetate pH 4.6
(Figure 28e) and many crystals were grown under these conditions. Crystals formed in
approximately one week period. Multiple single crystal formations were seen in each
well. These crystal formations were shot many times. The first had a resolutions of 4.5 Å.
The initial shape was hexagonal and the hypothesized space group was P622. However,
several different shapes were seen in each well. The next attempt had a resolution of 4.0 Å
and was triclinic. The unit cell for all these crystals shot were a=b=119.765 Å, c= 172.29.
The water content was 65%. Ultimately, the crystal formations yield a space group of
P321. The unit cells were a=b=207.88, c=172.1269. These crystals yielded a resolution of
2.9 Å. However, using Matthew’s coefficient, 12 residues were found per asymmetric
unit. A total of 300 frames were collected for the last attempt. Using Crystal Clear® the
data was integrated and an R factor of 12.5% was observed. The diffraction pattern is
shown in Figure 29.
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h.

Figure 28: Picture of crystal formations a, b- 30% PEG 4000, .1M Tris HCl, .2M Lithium
Sulfate c, d- 1.0M Ammonium Phosphate, .1M Na Citrate pH 5.6 e.- 1.2M Sodium
Formate, 0.1M Na Acetate pH 4.6 f.- .8M Ammonium Phosphate .1 M Na Citrate pH= 5.6
g.- .9M Ammonium Phosphate .1M Na Citrate pH=5.6 h.- 20% PEG 3350 .2 M Calcium
Acetate
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Table 3: Summary of crystal diffraction data for MtB TrmDz

Figure 29: X-Ray Diffraction Pattern of 1.2M Sodium Formate, 0.1M Na Acetate pH 4.6

67
Chapter 4
4.1 Discussion
TrmD functions catalytically as a ternary complex comprised of the trmD enzyme,
a tRNA substrate and the AdoMet cofactor. In the case of the E. Coli enzyme, the binding
of tRNA and AdoMet are not co-dependent, and the enzyme exhibits random sequential
kinetics. Studies in the Holmes lab suggest that only one AdoMet is bound not two in the
S. pneumonia TrmD protein (unpublished, M Palesis).
The kinetic assays of methylation done here show that the activity of methylation
occurs much slower in MtB than in the E. coli TrmD. The turnover number relates the
amount of product methylated per a unit of time, per molecule of enzyme. MtB is an
aerobic bacterium that divides every 16 to 20 hours, an extremely slow rate compared with
many other bacteria, which usually divide in less than an hour (5). Thus, the rate at which
methylation of tRNA occurs is important for maintaining tRNA methylation which is in
turn required for error free protein synthesis. The data presented here only provide an
initial study of the kinetics of the TrmD from TB. More extensive studies need to be
performed to properly compare rate constants of this enzyme to other known trmD
organisms.
It is clear that the TrmD protein is an important target for antimicrobial agents
because it has been shown to be essential in a number of eubacterial forms and is a protein
unique to eubacteria. All cellular forms contain enzymes that catalyze the AdoMet
dependent methylation of tRNA molecules at G37, a modification that prevents frame
shifting (22). Whereas most missense errors do not eliminate the activity and stability of
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proteins, frameshift errors which are the result of an inactive trmD gene are detrimental for
cellular viability (27). It is likely that maintenance of proper reading frames would be a
strongly conserved property of all cellular forms, and a prerequisite for the emergence of
the three domains of life, namely Archaea, Bacteria and Eukaryotes (7). Thus, this enzyme
is part of the minimal set of gene products required for the evolution of all cellular forms
(25). Mutational analysis performed in two bacterial species confirmed that a defect in the
protein will cause the bacterium to grow more slowly (E. coli) or be lethal to the organism
(S. pneumonia) (21). Deficiency of TrmD appears to have a global effect on cell
physiology. Bjork et. al. observed changes in carbon source metabolism and resistance or
sensitivity to amino acid analogs (26). In particular, lack of enzyme affects metabolism of
thiamine and pantothenate (27, 28).
This project included cloning, expression, characterization and crystallization of
Mycobacterium tuberculosis trmD. In the characterization experiments, kinetic assays
and some inhibitor work were performed to compare this enzyme with that of previous
data for other trmD orthologs determined by Holmes’s laboratory. We have not yet shown
that TrmD is an essential protein in the Mycobacteria, and this should be done if we are to
move ahead in the development of a new antimicrobial agent active against this organism.
Other issues that are important to deal with will be permeability problems of any drug
developed since the cell wall of Mycobacteria is very hydrophobic and relatively
impermeable. Other barriers will involve defeating pump mechanisms that might exist.
The enzyme was relatively easy to crystallize, and crystals were seen within one
week under certain conditions. Sodium formate crystals formed relatively quickly and
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were the largest seen. Considerable time was spent optimizing conditions with this
precipitant. It was observed that increasing protein concentration more than 22 mg/ml
produced showers of micro-crystals. Decreasing the protein concentration less than 12
mg/ml yielded no crystals. It was determined that a range of 12 to 20 mg/ml was optimal
for obtaining large crystals under these conditions. Other techniques employed (Dialysis
buttons, macro and micro-seeding) did not yield larger crystals. Magnesium was explored
as a factor for obtaining better crystals because it is required for optimal catalytic activity
for this enzyme.

Interestingly, magnesium actually prevented crystal formation. In

previous TrmD crystal structures no magnesium was ever seen. Perhaps its role is in post
tRNA interaction events such as base flipping in tRNA. Most previous TrmD proteins
were crystallized with AdoMet bound to enzyme, but we found that the M. tuberculosis
TrmD did not crystallize when AdoMet was added to protein samples at least under the
methods used here. Attempts in adding AdoMet directly in protein mixture or adding
AdoMet to protein and buffer mixture did not yield any crystals. Further work needs to be
performed on producing crystals with ligand bound to enzyme. It will be important to
obtain these co-crystals if inhibitors which bind this region are to be developed in order to
gain insight into overall enzyme mechanisms.
Other conditions for optimizing crystallization were explored to include
temperature and pH. It appears that pH’s near neutrality is important for the crystallization
of this protein. A reduced temperature of 10 ºC did not improve crystallization. If fact, no
crystals were formed after a month of incubation under this condition.
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Other precipitants were observed to crystallize the protein in the initial Hampton
screen. Crystals were seen under the following conditions: 1.2M Sodium Formate, 0.1M
Sodium Acetate pH= 4.6 (Figure 28e); 30% Polyethylene Glycol (PEG) 4000 0.1M Tris
HCl pH=8.5 .2M Lithium Sulfate (Figure 28 a,b); 1.0 M Ammonium Phosphate 0.1 M
Sodium Citrate pH=5.6 (Figure 28 c,d), 25% PEG 6000 .1M HEPES pH= 7.5; 20% PEG
3350 0.2M Calcium Acetate (Figure 28h); 20% PEG 3350 0.2M di-Ammonium Citrate;
40% PEG 200 0.1M MES pH=6.5 and 20% PEG 3350 0.2M di-Ammonium tartrate; 0.8M
Ammonium Phosphate, .1M Sodium Citrate pH=5.6 (Figure 28f); and .9M Ammonium
Phosphate, 0.1M Sodium Citrate pH=5.6 (Figure 28g). The following crystals were
selected for subsequent X-ray analysis: 1.2 M Sodium Formate, 0.1M Na Acetate pH=4.6;
1.0M Ammonium Phosphate, 0.1M Na Citrate pH=5.6; 20% Polyethylene Glycol (PEG)
3350 0.2M Calcium Acetate.
In the 1.0M Ammonium Phosphate 0.1M Na Citrate pH 5.6 (Figure 28c) buffer one
single crystal formed after three weeks. The resolution was 4.9 Å for this crystal form.
The spot intensity dropped after 7.8 Å and the shape was hexagonal. The unit cell
dimensions were a=b=119.765 Å, c= 172.29. After repeated optimization attempts larger
crystals were formed, however the larger crystals did not diffract.
In the 1.2 M Sodium Formate .1 M Sodium Acetate pH=4.6 the unit cells were
a=b=207.88, c=172.1269. Several crystals were analysed, and the final attempt with this
condition yeilded a resolution of 2.9 Å which was the best resolution seen in these studies.
The Programs Phoenix® and CCP4® were used to integrate the data. Using Matthew’s
coefficient, 12 residues were found per asymmetric unit and the solvent content was about
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57%. Matthew’s calculation estimates of the number of molecules per unit cell (Z).
Because of this, the structure proved to be very difficult to solve. This is part of the
symmetric object from which the whole is built up by repeats. During the last effort of
crystallography another protein condition yielded large crystals, 20% PEG 3350 0.2M diAmmonium tartrate. The unit cell was again a=b=207.88, c=172.1269. This is similar to
data for the sodium formate crystals.
After obtaining similar results for two different buffer conditions it can be inferred
that the enzyme itself does not pack properly. The number of molecules in the asymmetric
unit helps define the crystal packing as non-Centro symmetric. This is a space group
which lacks an inversion center. Center of Symmetry (or Center of Inversion) is a point
through which an inversion operation is performed, converting an object into its mirror
image. As a result of the high number of molecules per asymmetric unit the cell packing
is affected. A crystal is a three-dimensional periodic arrangement of molecules. When the
material precipitates from a solution, its molecules attempt to reach the lowest free energy
state. The search for a minimum free energy, and as a consequence the regular packing of
molecules in a crystal lattice, often leads to a symmetric relationship between molecules.
Due to the number of residues per asymmetric unit “loose” binding occurs between the
units. When the crystal does not have tight binding between units, packing issues arise
and resolution of the crystal is also affected.
Another issue to consider is the cryoprotectant Glycerol was the only
cryoprotectant used for crystals obtained. Initially, 20% glycerol was used to check
diffraction of the sodium formate crystals. However, it was noticed that as the amount of
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glycerol decreased, better resolution was observed. When collecting data for the last
crystal, 10% glycerol was used in 20% PEG 3350 .2M Calcium Acetate. Other options to
consider in the future involve trying different cryoprotectant conditions. A CryoPro® kit,
which includes 36 conditions available, produced by Hampton Research Company, was
considered for usage in the future.
An alternative we contemplated for future work involved protein modification. One
modification would be to remove the 6x His-tag from the protein. There are a number of
kits and protocols to assist in removal of the His-tag. Another mutation would involve
changing the amino acid sequence of the protein.
Why then, does the mycobacterial trmD enzyme pose such problems in packing?
One major difference exists from most other trmD genes.

The TrmD protein is

substaintially shorter than the E. coli and most other TrmD proteins. It has 231 amino
acid residues whereas E. coli has 255 residues. Therefore the final alpha helix seen with
the E. coli enzyme is absent from the Mycobacterial TrmD protein. If for example the C
terminus is a key stable contact point in crystals then other contact points may occur in the
Mycobacterial TrmD creating packing problems. For example, now the mobile his tag
sequences might create problems with the resulting heterogeneous packing that might
ensue. If this is true it will be important to remove the His tag sequence by proteolysis and
again attempt crystallization.
The pdb files of the following trmD enzymes were all viewed and compared:
Streptococcus pneumonia, Bartonella henselae, and Eschericha coli. After close
observation of the residues within the asymmetrical unit, it was found that the missing
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amino acids from the Mycobacterium tuberculosis organism greatly impacted the stability
of the structure. The residues at the C-terminus played an important role in interacting
between the residues of different lattices. Thus, packing of the crystal would be impacted
if those important interactions did not occur. This may account for the problems of low
resolution, diffraction and large numbers of residues per asymmetric unit.
One possible approach for improving crystal packing could involve the removal of
the His-tag which might introduce heterogenous packing. Alternatively, since many other
trmDs have been crystallized with the His-tag it seems reasonable the C-terminus contact
points were important. Therefore, if a terminal alpha helix were added to the TB protein
then better packing might be achieved.
In summary, we have initiated an extensive effort to obtain the crystal structure of
an important drug target from a very important pathogen. Considerable progress has been
made which point the way towards a successful solution of the structure.
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